 This paper examines the barriers to accessing CRT cell therapy in the four largest EU countries. The authors found that between 58% and 83% of patients diagnosed with relapsed slash refractory diffuse large B cell lymphoma, DLBCL, who received the EMA approved label were not treated with a CRT cell therapy in 2020. Common barriers to accessing this treatment included timely identification and referral of eligible patients, pretreatment funding approval by authorities and payers, and resource needs at CRT cell centers. To address these issues, the authors recommend that healthcare systems implement best practices and focus on specific areas such as timely identification, referral of eligible patients, pretreatment funding approval, and resource needs at CRT cell centers. This article was authored by Miguel Akanales-Albendia, Pier Luigi Canonico, Guillaume Carton, and others.